While the world obsesses over the next AI model, a quieter but equally ambitious race is underway: the race to slow, stop, or reverse aging itself.
This market is called longevity biotech, and billions of investment dollars are pouring into it.
Today, I’ll tell you about a tiny startup in this market called Biophysical Therapeutics.
The company is making a bold claim: it says it’s found nature’s “dial” for aging, and that it’s found a way to “bottle” that dial and sell it.
The thing is, this company is legitimate — and it’s currently raising capital from investors like you. So let’s dive in.
The Market Opportunity
The numbers are hard to ignore.
Longevity and anti-aging biotech has grown into a multi-tens-of-billions-dollar category, with venture capital flowing furiously even as other sectors cool.
At the same time, the mainstream market for anti-aging skincare and cosmetics sits in the tens of billions, and keeps expanding as populations age and consumers spend more on prevention.
What makes this sector so interesting for early-stage investors like us is the dual path it offers:
- A massive consumer market — skincare — that can generate revenue quickly.
- A much larger therapeutic market — for cancer, Alzheimer’s, and longevity drugs — that could deliver extraordinary upside if the science holds up.
Biophysical’s strategy is to start with the first path while it builds toward the second.
It’s a strong strategy. But how’s the science behind it?
The Science (and Credibility) Behind the Claim
The company’s core thesis centers on a protein called IF1.
According to founder Dr. Michael Forrest, IF1 acts as a natural regulator of aging rate across species. Simply put, more IF1 correlates with slower aging.
The company has published a quantitative model that, it claims, can predict lifespans of thousands of species, and it’s supported by experimental data points. For example, in mice, increasing IF1 appears to slow markers of aging.
That’s why the firm has filed patents, and is positioning this biology as the foundation for a topical product, as well as broader drug programs.
Furthermore, its advisors include heavyweight names like Harvard’s Professor George Church, and Professor Bruno Conti of Scripps Research, whose earlier work linked reduced metabolic heat generation to longer mouse lifespan. That pedigree gives the story credibility that many anti-aging startups lack.
Still, it’s early. Much of the key work remains at the preprint or preclinical stage. At the moment, human efficacy data for the skincare application is limited.
Path to Commercialization
This explains why, rather than diving straight into expensive clinical trials for a longevity drug, Biophysical is starting with skincare.
Its plan is to launch an IF1-based moisturizer under the brand IF1.skin, priced at $120 per unit. Because it’s positioned as a cosmetic, it avoids the long regulatory gauntlet of a pharmaceutical.
The company says it already has paid pre-orders and has run ad tests showing attractive unit economics (i.e., low customer acquisition costs relative to the high price point).
Proceeds from its current round of funding are earmarked to manufacture and fulfill the first batch of roughly 500 units. Success could create a self-funding flywheel: revenue and profit from the consumer product could help finance the longer-term drug pipeline targeting cancer and the diseases of aging.
It’s a classic “moonshot that pays its way” structure — if the product actually ships and sells.
The Team
This is essentially a founder-led effort. Dr. Michael Forrest, a Cambridge biochemistry graduate with a PhD in computer science, is CEO and the primary inventor.
Forrest has a track record of granted patents and positions himself as a computational biology specialist who’s moved from theory to experimentally-validated drug candidates.
The real gravitas of the company comes from its advisory board. Church and Conti are heavyweight names in biotech and longevity circles. Their network can open doors to partnerships, further research, and future funding rounds.
That being said, the existing operating team is lean. Execution risk sits heavily on Forrest’s shoulders.
Pros, Cons, and the Investment Case
The upside case is straightforward…
A differentiated scientific claim in a huge market, a low-barrier consumer entry point that can generate cash, and high-profile scientific advisors. If the skincare product works, and the broader platform produces real drugs, the valuation leap from the existing funding round (the valuation is just $8 million) could be enormous.
The risks are equally clear…
This is still an early-stage company with limited resources. Scientific claims need more independent validation. So far, consumer demand is small and partly driven by pre-orders. Manufacturing, shipping, and scaling a physical product introduce classic operational hurdles. And the longevity space is crowded.
In short: this is a high-risk, high-potential bet on science and execution.
That’s why I’m not recommending that you blindly invest in it. As always, you need to do substantial research before making an investment decision. (Or let us do the research for you!)
But if you’re looking to invest in the exciting and fast-growing market for longevity biotech, this could be a great place to start your search.
You can learn more about the company and its funding round here »
Happy Investing,
Please note: Crowdability has no relationship with Biophysical Therapeutics, or with any of the startups we write about. We’re an independent provider of education and research on startups and alternative investments.
